science
Ivonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
May 31, 8:00 AM·1m read1 source
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Ivonescimab reduced the risk of death by 34 percent compared with a standard treatment in patients with squamous non-small cell lung cancer, according to trial data presented Sunday. The study was conducted entirely in China by Akeso Therapeutics. The drug combines the activity of two of the best-selling cancer medicines.
It is being developed outside China by Summit Therapeutics. Results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago and published simultaneously in The Lancet. ” Akeso had no comment for this story.
The article was written by Matthew Herper and published May 31, 2026, by STAT as an exclusive STAT+ story.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
